The price of global health : drug pricing strategies to balance patient access and the funding of innovation
著者
書誌事項
The price of global health : drug pricing strategies to balance patient access and the funding of innovation
（A Gower book）
Routledge, Taylor & Francis Group, 2016
2nd ed
- : hbk
大学図書館所蔵 件 / 全1件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Previous edition: 2011
Includes bibliographical references and index
内容説明・目次
内容説明
Public debate on the rising cost of new biotechnology drug treatments has intensified over the last few years as healthcare budget pressures have mounted under a strained economy. Meanwhile, the demand for new, effective medical and drug treatments continues to rise as unhealthy lifestyles cause further increases in diabetes and cardiovascular disease. Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How should drug prices be set and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? How can a life-saving industry have a poorer image than gun and tobacco industries, whose products are associated with death? Ed Schoonveld explains how pharmaceutical prices are determined in a complex global payer environment and what factors influence the process. His insights will help a wide range of audiences, from healthcare industry professionals to policy makers and the broader public, to gain a better understanding of this highly complex and emotionally charged field. The Price of Global Health is recognized as a valued and unique reference book that covers a complete array of topics related to global pharmaceutical pricing. It contains an in-depth but straightforward exploration of the pharmaceutical pricing strategy process, its underlying market access, general business and ethical considerations, and its implications for payers, physicians and patients. It is a much-needed and invaluable resource for anybody interested or involved in, or affected by, the development, funding and use of prescription drugs. In particular, it is of critical importance to pharmaceutical company executives and other leaders and professionals in commercialization and drug development, including marketing, business development, market access and pricing, clinical development, drug discovery, regulatory affairs, health outcomes, market research and public affairs. The second edition includes new chapters on payer value story development, oncology, orphan drugs and payer negotiations. Furthermore, many country chapters have been substantially updated to reflect changes in the healthcare systems, including the Affordable Care Act in the US, AMNOG in Germany, medico-economic requirements in France and many other country-specific changes. Lastly, almost every chapter has been updated with new examples and illustrations.
目次
- Contents: Foreword, Andrea Mantovani
- Preface
- Introduction. Part A Drug Market Access and Pricing Basics: The drug pricing challenge
- Payers
- Fundamentals of pricing
- Reference-based pricing
- Health outcomes and health economics
- Features, benefits, value and price. Part B Structured Market Access and Pricing Approaches: Pricing and drug development
- Payer segmentation
- Key situation factors: the PODiUM approach
- The BEST PRICE framework to market access and pricing
- Payer value story. Part C Developing an Integrated Global Strategy: Developing a global pricing strategy
- Public policy and ethical considerations
- Oncology and orphan drugs
- Payer and pricing research. Part D Market Access and Pricing Strategy Implementation: Corporate market access and pricing function
- Market access and pricing negotiations
- Risk sharing and managed entry agreements. Part E Key Healthcare Systems: United States
- Canada
- France
- Germany
- Italy
- Spain
- UK
- Japan
- Australia
- Brazil
- China
- India
- South Korea. References
- Index.
「Nielsen BookData」 より
